• 1. An autonomous self-optimizing flow machine for the synthesis of pyridine–oxazoline (PyOX) ligands?
  Eric Wimmer,Daniel Cortés-Borda,Solène Brochard,Elvina Barré,Charlotte Truchet,Fran?ois-Xavier Felpin React. Chem. Eng., 2019,4, 1608-1615
• 2. An alkynylboronatecycloaddition strategy to functionalised benzyne derivatives?
  James D. Kirkham,Patrick M. Delaney,George J. Ellames,Eleanor C. Row,Joseph P. A. Harrity Chem. Commun., 2010,46, 5154-5156
• 3. An intramolecular tryptophan-condensation approach for peptide stapling?
  Eunice Y.-L. Hui,Bhimsen Rout,Yaw Sing Tan,Kok-Ping Chan,Charles W. Johannes Org. Biomol. Chem., 2018,16, 389-392
• 4. Acetylcholinesterase amperometric detection system based on a cobalt(II) tetraphenylporphyrin-modified electrode
  Analyst, 1996,121, 1123-1126
• 5. An amplified fluorescence detection of T4 polynucleotide kinase activity based on coupled exonuclease III reaction and a graphene oxide platform?
  Ni-Na Sun,Fengli Qu,Xiaobing Zhang,Shufang Zhang,Jinmao You Analyst, 2015,140, 1827-1831

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazines Halopyrimidines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazines Pyrimidines and pyrimidine derivatives Halopyrimidines

Recent Advances in the Study of 5-bromo-2-(1-chloroethyl)pyrimidine (CAS: 1514124-47-0)

The compound 5-bromo-2-(1-chloroethyl)pyrimidine (CAS: 1514124-47-0) has recently garnered significant attention in the field of chemical biology and medicinal chemistry due to its potential applications in drug discovery and development. This heterocyclic compound, characterized by its pyrimidine core substituted with bromo and chloroethyl groups, has been the subject of several studies aimed at exploring its synthetic utility, biological activity, and mechanism of action. In this research brief, we summarize the latest findings related to this compound, highlighting its role as a versatile building block in organic synthesis and its emerging therapeutic potential.

Recent synthetic studies have demonstrated the efficacy of 5-bromo-2-(1-chloroethyl)pyrimidine as a key intermediate in the preparation of more complex heterocyclic systems. Researchers have employed this compound in palladium-catalyzed cross-coupling reactions, such as Suzuki-Miyaura and Buchwald-Hartwig couplings, to introduce pyrimidine moieties into target molecules. The presence of both bromo and chloroethyl substituents allows for selective functionalization, enabling the synthesis of diverse derivatives with tailored properties. These synthetic methodologies have been optimized to achieve high yields and excellent regioselectivity, making this compound a valuable tool for medicinal chemists.

In the realm of biological activity, preliminary investigations have revealed that 5-bromo-2-(1-chloroethyl)pyrimidine exhibits promising inhibitory effects against certain kinase targets implicated in cancer and inflammatory diseases. Structure-activity relationship (SAR) studies have shown that modifications to the chloroethyl group can significantly influence the compound's potency and selectivity. Molecular docking simulations suggest that the pyrimidine ring forms key hydrogen bonds with active site residues, while the bromo substituent contributes to hydrophobic interactions. These findings have spurred further optimization efforts to develop more potent and selective analogs.

From a mechanistic perspective, recent studies have begun to elucidate the compound's mode of action at the molecular level. Biochemical assays indicate that 5-bromo-2-(1-chloroethyl)pyrimidine acts as an ATP-competitive inhibitor for certain protein kinases, disrupting phosphorylation cascades critical for cell proliferation and survival. Additionally, mass spectrometry studies have identified covalent adduct formation between the chloroethyl group and cysteine residues in target proteins, suggesting a dual mechanism of inhibition. This unique property has generated interest in developing targeted covalent inhibitors based on this scaffold.

The pharmacokinetic profile of 5-bromo-2-(1-chloroethyl)pyrimidine and its derivatives has also been investigated in recent preclinical studies. While the parent compound demonstrates moderate metabolic stability in liver microsome assays, strategic modifications to the pyrimidine core have yielded analogs with improved oral bioavailability and tissue distribution. These advancements have paved the way for further in vivo evaluation of this compound class in disease-relevant animal models.

Looking forward, the versatility of 5-bromo-2-(1-chloroethyl)pyrimidine as both a synthetic intermediate and a bioactive scaffold positions it as a valuable asset in drug discovery pipelines. Current research efforts are focused on expanding its applications to other therapeutic areas, optimizing its drug-like properties, and exploring combination therapies. As these investigations progress, this compound is expected to play an increasingly important role in the development of novel therapeutic agents targeting various diseases.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)